Compare GE Vernova Inc (GEV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs BIO-TECHNE Corp — how do they compare? GE Vernova Inc trades at $1,005.52 (market cap $266.16B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: GE Vernova Inc is far larger — about 23.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and BIO-TECHNE Corp for 63 Days on average.
| GEV | TECH | |
|---|---|---|
Market Cap | $266.16B | $11.36B |
Volume | 2,324,165 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $1.17K | $72.61 |
52-Week Low | $547.96 | $43.31 |
Typical Hold Time | 36 Days | 63 Days |
Enterprise Value | $255.83B | $11.39B |
Dividend Yield | 0.2% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $986.62, down 1.05% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical momentum with support at $973 and resistance at $1,026. Recent Q1 2026 earnings beat expectations with EPS of $17.44 versus $1.95 expected, while Q2 2026 missed estimates. The company secured the first US construction permit for its BWRX-300 small modular reactor, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with projected revenue growth to $41.4B in 2026 and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and EV/EBITDA of 85.22, plus execution challenges in scaling nuclear projects. The stock offers exposure to AI infrastructure growth but requires monitoring of margin expansion and backlog conversion.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
